Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LMY-922 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LMY-922, putative chimeric antigen receptor (CAR) T-cell therapy expressing B-cell activating factor (BAFF) (Jul 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LMY-922 | LMY922|LMY 922 | Limited information is currently available on LMY-922, putative chimeric antigen receptor (CAR) T-cell therapy expressing B-cell activating factor (BAFF) (Jul 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07679919 | Phase I | LMY-922 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Not yet recruiting | USA | 0 |